Compare EPRT & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPRT | LNTH |
|---|---|---|
| Founded | 2016 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.5B |
| IPO Year | 2018 | 2014 |
| Metric | EPRT | LNTH |
|---|---|---|
| Price | $30.70 | $99.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 6 |
| Target Price | $36.79 | ★ $87.00 |
| AVG Volume (30 Days) | ★ 1.2M | 977.3K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | ★ 11.30 | N/A |
| EPS | 0.28 | ★ 1.80 |
| Revenue | ★ $561,219,000.00 | $343,374,000.00 |
| Revenue This Year | $17.12 | N/A |
| Revenue Next Year | $16.27 | $14.19 |
| P/E Ratio | $110.82 | ★ $55.18 |
| Revenue Growth | ★ 24.82 | 3.62 |
| 52 Week Low | $28.95 | $47.27 |
| 52 Week High | $34.73 | $102.66 |
| Indicator | EPRT | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 40.66 | 67.78 |
| Support Level | $29.24 | $91.65 |
| Resistance Level | $31.92 | N/A |
| Average True Range (ATR) | 0.45 | 3.13 |
| MACD | 0.02 | 0.17 |
| Stochastic Oscillator | 41.06 | 66.35 |
Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses. The Company generally invests in and leases freestanding, single-tenant commercial real estate facilities where a tenant services its customers and conducts activities that are essential to the generation of the tenant's sales and profits.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.